15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 12 firms covering Celldex Therapeutics Inc, 11 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets range widely, $34.00 to $100.00 (about 2.9x), a sign of real disagreement on valuation. The average target of $53.50 sits 50% above the current $35.60. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 9 to 11 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-1.08 next quarter toward $-4.44 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS12 ratings
Strong Buy
Strong Buy00%
Buy1192%
Hold18%
Sell00%
Strong Sell00%
Based on 12 analysts giving stock ratings to Celldex Therapeutics Inc.
As of Jul, 11 of 12 firms rate CLDX a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
CLDX EPS & revenue forecast
EPS · NEXT QUARTER
$-1.08
Range $-1.20 – $-0.94 · 10 analysts · +7% YoY
Next period, 10 analysts expect Celldex Therapeutics Inc to earn $-1.08 a share (range $-1.20 – $-0.94), versus $-1.01 a year earlier. Full-year consensus is $-4.39, growing to $-4.44 the year after.
REVENUE · NEXT QUARTER
$939.9K
Range $0 – $3.0M · 10 analysts
Revenue is expected to reach $939.9K (range $0 – $3.0M). Full-year consensus is $2.4M, rising to $11.0M next year.
Top analysts covering Celldex Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on CLDX.
#1
Yatin Suneja
Guggenheim · Rank #28
Buy
$100.00+180.9% to target
Overall win rate
52%
+ Follow
#2
Kristen Kluska
Cantor Fitzgerald · Rank #162
Buy
$61.00+71.3% to target
Overall win rate
38%
+ Follow
#3
Joseph Pantginis
HC Wainwright & Co. · Rank #266
Buy
$42.00+18.0% to target
Overall win rate
32%
+ Follow
#4
Derek Archila
Wells Fargo · Rank #350
Buy
$48.00+34.8% to target
Overall win rate
32%
+ Follow
#5
Etzer Darout
Barclays
Buy
$48.00+34.8% to target
Coverage
—
+ Follow
CLDX stock forecast FAQ
What is CLDX's average 12-month price target?+
The 12 analysts with a live target average $53.50 for Celldex Therapeutics Inc over the next 12 months, ranging from a $100.00 high to a $34.00 low.
Is CLDX stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 12 analyst ratings, 11 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for CLDX?+
The Street-high target is $100.00 (Guggenheim), and the Street-low is $34.00 (Goldman Sachs). The average of all 12 active targets is $53.50.
How many Wall Street analysts cover CLDX?+
12 analysts have an active rating on Celldex Therapeutics Inc, and 12 firms carry a live 12-month price target.
Who is the most accurate analyst covering CLDX?+
Among analysts who currently cover CLDX, Yatin Suneja of Guggenheim has the strongest overall Quantellect track record (Rank #28). Their current call is Buy with a $100.00 target.
What is Celldex Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-1.08 per share (range $-1.20 – $-0.94) across 10 analysts. Full-year EPS is projected at $-4.39, rising to $-4.44 the following year.
How much revenue is Celldex Therapeutics Inc expected to report next quarter?+
Consensus revenue is $939.9K (range $0 – $3.0M). Full-year revenue is projected at $2.4M, growing to $11.0M next year.
Have analysts been upgrading or downgrading CLDX lately?+
As of Jul, 11 of 12 firms rate CLDX a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their CLDX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
